Cartesian Therapeutics (RNAC) Other Non-Current Assets (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Other Non-Current Assets of $1.7 million for Q1 2026, up 3.95% year-over-year from $1.7 million in Q1 2025, and little changed quarter-over-quarter from $1.7 million in Q4 2025.
Cartesian Therapeutics (RNAC) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Other Non-Current Assets for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 3.95% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 3.95% YoY), while the FY2025 annual figure was $1.7 million, up 234.94% from the prior year.
- Other Non-Current Assets was little changed at $1.7 million in Q1 2026 per RNAC's latest filing, from $1.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.6 million in Q2 2025 and bottomed at $518000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $1.9 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 62.38% — and 2025, when it soared 234.94%.
- Cartesian Therapeutics' Other Non-Current Assets stood at $1.6 million in 2022, then declined by 13.94% to $1.4 million in 2023, then tumbled by 62.38% to $518000.0 in 2024, then jumped by 234.94% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
- Business Quant data shows RNAC's Other Non-Current Assets at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.78 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 5.55 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 1.67 Mn |
| Dec 31, 2024 | 518,000.00 |
| Sep 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.38 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.38 Mn |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 1.38 Mn |
| Sep 30, 2021 | 1.38 Mn |